Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Marker for ovarian cancer and application thereof

A technology of drugs, chemotherapy drugs, applied in the field of medical biology, to achieve the effect of promoting progress

Pending Publication Date: 2022-05-13
SHENGJING HOSPITAL OF CHINA MEDICAL UNIV
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Function of PRPF6 unreported in other cancers including ovarian cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Marker for ovarian cancer and application thereof
  • Marker for ovarian cancer and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] Example 1 PRPF6 is up-regulated in chemotherapy-resistant tissues and is associated with FIGO stage of ovarian cancer.

[0036] In order to explore the difference in the expression of PRPF6 in chemotherapy-resistant tissues, we analyzed the differential expression of PRPF6 in the chemotherapy-sensitive ovarian cancer cell line SKOV3 and the chemotherapy-resistant cell line SKOV3-TR30. Through PCR detection, it was found that PRPF6 was relatively up-regulated in SKOV3-TR30 compared with SKOV3 ( figure 1 A). IHC was used to detect the expression of PRPF6 in primary cancer tissues. PRPF6 was relatively higher in chemotherapy-resistant ovarian cancer tissues (N=20) than in chemotherapy-sensitive tissues (N=32, figure 1 B). Then, we investigated the relationship between PRPF6 expression and clinicopathological features. The results showed that PRPF6 was closely related to FIGO stage and not related to age, degree of differentiation and lymph node metastasis (Table 1).

...

Embodiment 2

[0039] Example 2 PRPF6 promotes tumorigenesis, epithelial-mesenchymal transition, and paclitaxel resistance in ovarian cancer cells and in vivo.

[0040] The siRNA of PRPF6 was transfected into SKOV3-TR30 cells, and the overexpression plasmid PC-DNA3.1-PRF6 was stably transfected into SKOV3 cells. CCK results showed that knockdown of PRPF6 and overexpression of PRPF6 significantly inhibited and promoted cell growth, respectively ( figure 2 A). Clonogenic assays also showed similar effects ( figure 2 B). Transwell analysis showed that knockdown of PRPF6 resulted in decreased cell invasion and migration, while overexpression of PRPF6 resulted in increased invasion and migration ( figure 2 C). Drug sensitivity experiments showed that knockdown of PRPF6 suppressed paclitaxel resistance, while high expression of PRPF6 promoted paclitaxel resistance ( figure 2 D). Flow cytometry showed that knockdown of PRPF6 induced apoptosis, while overexpression of PRPF6 was the opposit...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of medical biology, and particularly relates to an ovarian cancer marker and application thereof. The invention proposes that the expression level of PRPF6 in ovarian cancer is closely related to FIGO staging and is irrelevant to age, differentiation degree and lymph node metastasis for the first time. The expression levels of the PRPF6 gene and the encoded protein thereof in the ovarian cancer drug-resistant cells / tissues are detected through PCR, immunohistochemistry and other methods, high expression of the PRPF6 in the drug-resistant cells / tissues is found, and it is clear that the PRPF6 can be used as the ovarian cancer paclitaxel drug-resistant marker. By inhibiting the expression level of the PRPF6, the drug resistance of paclitaxel can be inhibited, the invasion and migration of ovarian cancer cells can be reduced, cell apoptosis can be induced, and tumor growth can be inhibited, so that the PRPF6 inhibitor can be used as a potential target spot for the paclitaxel chemotherapy drug resistance treatment of the ovarian cancer, and a reference basis is provided for clinical diagnosis and treatment of the chemotherapy drug resistance type ovarian cancer. The method has wide application prospects and huge potential social benefits.

Description

technical field [0001] The invention belongs to the technical field of medicine and biology, and in particular relates to a marker of ovarian cancer and its application. Background technique [0002] Ovarian cancer (OC) is one of the female malignancies with high morbidity and mortality worldwide. Since the early clinical manifestations of ovarian cancer patients have no obvious specificity, the early diagnosis rate in our country is low, and most of the ovarian cancer patients are in the advanced stage, although the 5-year survival rate is very low despite cellular decompression combined with radiotherapy and chemotherapy. Paclitaxel is currently a widely used anti-tumor chemotherapy drug. However, long-term treatment can make tumor cells resistant to it, which is the main reason for the failure of chemotherapy. Therefore, in-depth research on ovarian cancer chemotherapy resistance, finding effective and reliable drug resistance markers, and developing related drugs to re...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/6886G01N33/574C12N15/113A61K45/06A61K31/713A61K31/337A61P35/00
CPCC12Q1/6886G01N33/57449G01N33/57484C12N15/113A61K45/06A61K31/713A61K31/337A61P35/00C12Q2600/158G01N2333/47C12N2310/141A61K2300/00
Inventor 王敏王涵张思杨周莹莹曾志漆雅陶陶
Owner SHENGJING HOSPITAL OF CHINA MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com